Eugia recalls one nationwide lot of injectable vancomycin after glass particle found in vial

Eugia US LLC, formerly known as AuroMedics Pharma LLC, is recalling one nationwide lot of its injectable antibiotic vancomycin hydrochloride after discovering a glass particle inside a vial, according to a notice posted by the Food and Drug Administration. The drug, sold under the Eugia label and used almost exclusively in hospitals and infusion clinics to fight serious bacterial infections, was shipped to wholesalers across the country for two weeks in early September before the contamination was caught.

The affected product is Vancomycin Hydrochloride for Injection USP, 1.25 grams per 30 mL, packaged as a single-dose vial, lot number 3VM26026A, carrying the National Drug Code numbers 55150-471-01 (vial) and 55150-471-10 (carton). The lot does not expire until July 2028 and was distributed to wholesalers nationwide between September 2 and September 15, 2026, the company said in its own recall notice. Eugia announced the recall on November 6; the FDA's public database listing went up three days later, on November 9. As of this writing, the agency had not yet assigned the recall a formal severity rating.

A sliver of glass in an IV bag

The recall was triggered after a glass fragment was found inside one vial during routine inspection, and it has been extended to the hospital, healthcare-facility and user level — meaning it reaches not just distributors and pharmacies but the bedside. Because vancomycin for injection is administered directly into a patient's bloodstream, any solid contaminant poses a different order of risk than it would in a pill swallowed and digested normally.

"Greater susceptibility may exist in neonates, infants and patients with compromised organ function," the company wrote in its recall notice, describing the population most likely to be harmed by the glass particles.

Eugia's notice states there is a reasonable probability that a particle entering the bloodstream could block or clot blood vessels, reduce blood flow to vital organs, trigger a pulmonary embolism, or cause permanent organ damage or death. Less severe effects could include irritation of the vein, inflammatory reactions at the injection site, aggravation of the infection already being treated, or an allergic reaction. The company says it has received no reports to date of any patient actually being harmed by product from this lot.

Why vancomycin matters in hospitals

Vancomycin is one of the oldest and most heavily relied-upon antibiotics for infections resistant to more common drugs, including methicillin-resistant Staphylococcus aureus, or MRSA, a bacterium the Centers for Disease Control and Prevention has long tracked as a persistent threat in hospitals and nursing homes. The injectable form recalled here is used for bloodstream infections, infective endocarditis, bone infections, and serious skin and respiratory infections in both adults and children, including newborns. It is given only by IV drip or infusion pump, typically under a clinician's supervision, which is why hospitals and infusion pharmacies — not retail customers — hold the bulk of the supply.

That distinction matters for a separate, much more common form of the drug: oral vancomycin capsules and solution, prescribed for intestinal infections such as C. difficile colitis, are not part of this recall and are unaffected. Patients taking vancomycin by mouth have no reason to stop or change anything because of this notice.

Who needs to act

The practical burden falls on supply chains, not individual patients. Wholesalers, hospitals, pharmacies, infusion centers and prescribers that still hold vials from lot 3VM26026A are being told to stop using the product immediately and quarantine remaining inventory. Any institution that further distributed the lot to another facility is responsible for notifying that downstream recipient, and hospitals are expected to alert their own clinical staff. Eugia is arranging returns and replacements through a third-party recall processor and is handling medical questions and adverse-event reports through its own pharmacovigilance line.

A small number of patients receiving long-term intravenous antibiotics at home through infusion pharmacies could also be affected if their supply happened to come from the recalled lot; those patients are generally advised to check with their infusion provider rather than independently discarding medication, and to continue their prescribed antibiotic course unless a clinician tells them otherwise. Anyone who develops pain, redness or swelling along a vein, a fever, a rash, or sudden shortness of breath after an infusion is advised to contact a clinician promptly, and either the prescriber or the patient can report the problem through the FDA's MedWatch adverse-event reporting program.

Part of a recurring pattern

This is not the first time glass contamination has forced an injectable vancomycin recall. Hospira, now part of Pfizer, pulled a lot of 1.5-gram vancomycin vials in a Class I recall after visible glass particulates were spotted inside a vial, one of several similar actions against different manufacturers of the drug over the past several years. The FDA's drug recall database lists particulate matter — glass, rubber, fiber or other foreign material — as a recurring reason manufacturers pull sterile injectable products, reflecting the exacting manufacturing standards required for anything delivered directly into the bloodstream. Outside outlets covering this latest recall, including Medical Daily and Newsroom America, reported the same particulars Eugia and the FDA disclosed: one lot, no confirmed injuries so far, and a risk profile centered on patients who are already critically ill.

What happens next

The FDA has not yet published a severity classification for the recall, a step that typically follows its own review of the company's reasoning and risk assessment. Eugia says it is continuing to notify distributors and customers by recall letter and expects to complete returns and replacements of the affected lot in the coming weeks. For now, the agency and the company agree on the central point: no injuries have been confirmed, but the potential harm from an undetected glass particle in an IV antibiotic is serious enough to pull an entire production lot rather than wait and see.